Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
09:50am, Thursday, 14'th Nov 2024
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Jazz (JAZZ) Upgraded to Buy: Here's Why
01:06pm, Wednesday, 13'th Nov 2024
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 13'th Nov 2024
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
11:00am, Wednesday, 13'th Nov 2024
The mean of analysts' price targets for Jazz (JAZZ) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
10:20am, Monday, 11'th Nov 2024
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
12:00pm, Thursday, 07'th Nov 2024
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
08:01pm, Wednesday, 06'th Nov 2024
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
07:01pm, Wednesday, 06'th Nov 2024
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.61 per share, beating the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.84 per share a year ago.
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
06:15pm, Wednesday, 06'th Nov 2024
Jazz Pharmaceuticals plc JAZZ reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
04:05pm, Wednesday, 06'th Nov 2024
– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC
THE RITZ-CARLTON, NAPLES DEBUTS "NYE BLACK-TIE GALA" WITH ACCLAIMED JAZZ SENSATION STELLA COLE
03:35pm, Monday, 04'th Nov 2024
Celebrate in style with an unparalleled evening of dining, dancing and music in Naples' premiere luxury setting. NAPLES, Fla.
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics
10:21am, Monday, 04'th Nov 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Jazz (JAZZ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart
First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiop
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 30'th Oct 2024
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
04:15pm, Wednesday, 23'rd Oct 2024
DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the c
